Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinopathy of Prematurity Clear all
Completed No phase listed Observational

ROP Check Database Premature Infant Outcomes

NCT07312669
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Not listed
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
Not listed
Enrollment
7,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 21, 2026, 12:39 PM EDT
Withdrawn Phase 2 Interventional

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

NCT01232777
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
30 Weeks to 36 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 3 Interventional

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

NCT00000156
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Goggles, Ambient Light Reduction
Device · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Up to 1 Day
Timeline
Started 1995
U.S. locations
3
States / cities
Buffalo, New York • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2006 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated Not applicable Interventional

Use of Sucrose to Relieve Pain During Eye Exams in Infants

NCT00161694
View directory record Official record
Conditions
Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions
sucrose solution
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
5 Weeks and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Jul 21, 2026, 12:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for Severe ROP and Treatment on Visual Outcomes

NCT01559571
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 7 Days
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
South Bend, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 3 Interventional Results available

Rainbow Extension Study

NCT02640664
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 21, 2026, 12:39 PM EDT
Recruiting No phase listed Observational

Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity

NCT06612541
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), ROP Examination
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
24 Weeks to 34 Weeks
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 21, 2026, 12:39 PM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated No phase listed Observational

Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project

NCT02257307
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
RetCam retinal imaging used for routine care
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
32 Weeks to 40 Weeks
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Baltimore, Maryland • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated Not applicable Interventional Results available

Proparacaine and Mydriatic Eye Drops

NCT01266824
View directory record Official record
Conditions
Pain, Retinopathy of Prematurity
Interventions
Proparacaine Hydrochloride Ophthalmic Solution
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

NCT00349726
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 6 Days
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 21, 2026, 12:39 PM EDT
Completed No phase listed Observational

39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity

NCT01993043
View directory record Official record
Conditions
ROP Threshold
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Weeks to 40 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
2
States / cities
Houston, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated No phase listed Observational

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

NCT04506619
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Interventions
No Intervention
Other
Lead sponsor
Oak Hill Bio Ltd
Industry
Eligibility
12 Months to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
South Bend, Indiana • Jackson, Mississippi • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 12:39 PM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab Treatment For Type 1 ROP

NCT04634578
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

NCT02390531
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
11
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jul 21, 2026, 12:39 PM EDT
Not listed Not applicable Interventional

Eye Shields for Infants After Dilated Exam

NCT04519060
View directory record Official record
Conditions
Infant, Newborn, Disease, Pain, Retinopathy of Prematurity, Eye Diseases
Interventions
phototherapy eye shield
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 1 Year
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jul 21, 2026, 12:39 PM EDT
Not listed Phase 2Phase 3 Interventional

Cysteine Supplementation in Critically Ill Neonates

NCT00254176
View directory record Official record
Conditions
Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
Interventions
Parenteral cysteine-HCl supplementation, Placebo - added premasol
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 30 Days
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jul 21, 2026, 12:39 PM EDT
Not listed Phase 2Phase 3 Interventional

The Early Treatment for Retinopathy of Prematurity Study (ETROP)

NCT00027222
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
retinal ablation
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
0 Years to 42 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:39 PM EDT
No Longer Available No phase listed Expanded access

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

NCT00870636
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
30 Weeks and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

NCT02386839
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
rhIGF-1/rhIGFBP-3
Drug
Lead sponsor
Shire
Industry
Eligibility
40 Weeks to 108 Weeks
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Mobile, Alabama • Greenville, North Carolina • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 21, 2026, 12:39 PM EDT
Terminated No phase listed Observational

ROP Screening: Comparison of Pain Using Two Eyelid Retractors

NCT02152046
View directory record Official record
Conditions
Pain During ROP Exam
Interventions
ROP exam with spring loaded retractor, ROP exam with screw retractor
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
23 Weeks to 37 Weeks
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 21, 2026, 12:39 PM EDT